IDM Pharma, Inc. (IDM) is a biopharmaceutical company focused on the development of cancer products that either destroy cancer cells by activating the immune system or prevent tumor recurrence by triggering an adaptive immune response. The Company’s principal product candidate, mifamurtide (L-MTP-PE), also called MEPACT in Europe, is part of a family of immunotherapeutic agents that activate the body’s natural defenses. L-MTP-PE activates macrophages in-vivo (inside the body), in order to enhance their ability to destroy cancer cells. As of December 31, 2007, it is developing L-MTP-PE for the treatment of osteosarcoma, the common type of bone cancer. L-MTP-PE has received orphan drug designation in the United States and the European Union for this indication, permitting it to benefit from a set of laws encouraging the development of treatments for rare diseases. (Source: 10-K)
Medistem Laboratories is an innovative biotechnology company committed to the creation and commercialization of advanced medical therapies based on non-controversial adult stem cells. Medistem's corporate mission is to transform these stem cells into valuable medical treatments. The Company's business strategy calls for the establishment of a series of clinics and laboratories around the world to deliver unprecedented, next-generation cell therapies to help millions of patients while seeking to commercialize products in the U.S. market. Clinic treatments use proprietary technology and cells sourced from umbilical cords, fat, bone marrow, and muscle for the treatment of cerebral palsy, stroke, cardiovascular disease and orthopedic diseases. Medistem believes it may hold a substantial competitive edge in the worldwide emerging market for stem cell-sourced medical solutions, positioning it to become a leading global provider of stem cell treatments on a fee-for-service basis, while accumulating intellectual property based on clinical and laboratory findings.
Dragon Pharmaceutical Inc. (Dragon) is an international pharmaceutical company. Dragon produces and supplies a line of antibiotic products covering intermediates, active pharmaceutical ingredients and formulation drugs. The Company is a manufacturer and distributor of a broad line of antibiotic products, including 7-ACA, a key intermediate to produce cephalosporin antibiotics, Clavulanic Acid, and formulated cephalosporin antibiotic drugs. Dragon is a 7-ACA producer and a manufacturer of Clavulanic Acid products in China. In April 2008, the Company announced that it has realigned its business segments into two divisions: Cephalosporin and Penicillin.
Tercica is a biopharmaceutical company committed to improving endocrine health by partnering with the endocrine community to develop and commercialize new therapeutics for short stature and other metabolic disorders.
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage drug candidates for central nervous system disorders, with exclusive worldwide commercial rights to three product candidates in clinical development. The Company’s product portfolio includes Fiapta (iloperidone), a compound for the treatment of schizophrenia and bipolar disorder; VEC-162, a compound for the treatment of sleep and mood disorders, and VSF-173, a compound for the treatment of excessive sleepiness. (Source: 10-K)
Altus Pharmaceuticals Inc. (Altus) is a biopharmaceutical company focused on the development of oral and injectable protein therapeutics for gastrointestinal and metabolic disorders, with three product candidates in clinical development. The Company uses its protein crystallization technology to develop protein therapies. Its product candidates are designed to either substitute a protein that is in short supply in the body, or degrade toxic metabolites in the gut and remove them from the blood stream. It has initiated its Phase III clinical program for Trizytek (formerly ALTU-135) for the treatment of malabsorption due to exocrine pancreatic insufficiency and has completed a Phase II clinical trial of ALTU-238 in adults for the treatment of growth hormone deficiency. The Company is also conducting a Phase I clinical trial for ALTU-237. ALTU-237 is designed to treat hyperoxalurias. In addition, it has a pipeline of other product candidates in preclinical research and development. (Source: 10-K)
Domantis Limited develops the next generation of antibody molecules: Human Domain Antibodies. Domain AntibodiesÔ (dAbsÔ) are therapeutic molecules that have benefits of both small molecules and conventional antibodies. Like small molecules, dAbs are small in size and highly stable, resulting in a choice of therapeutic formats, delivery formulations and manufacture options. And like human antibodies, dAbs can be designed to have specificity and high affinity for the biological target of interest. Therapeutic leads include dAbs that uniquely neutralise (but not agonise) cytokine receptor targets, and Dual Targeting dAbs that can bind two therapeutic targets in one easily produced molecule. Due to its exclusive intellectual property and technology position for Domain Antibodies, Domantis is the only company capable of fully exploiting human Domain Antibodies.
AVI BioPharma, Inc. (AVI) is a biopharmaceutical company developing therapeutic products principally based on third-generation NeuGene antisense technology. The Company’s principal products in development target life-threatening diseases, including cardiovascular, infectious, and genetic diseases. AVI’s lead product candidate, Resten-NG is targeted at cardiovascular disease. AVI has completed pre-clinical and some clinical studies using its NeuGene drugs in the treatment of cardiovascular disease, infectious disease, cancer, polycystic kidney disease (PKD), in regulating drug metabolism via the P450 cytochrome system. The Company is conducting a Phase Ib/II clinical trial for coronary artery bypass grafting in eastern Europe. It is also conducting a proof of concept study in boys with Duchenne Muscular Dystrophy (DMD) in the United Kingdom, in collaboration with the MDEX consortium. In March 2008, the Company completed the acquisition of Ercole Biotechnology Inc.
Alkermes, Inc (Alkermes) is a biotechnology company. The Company manufactures RISPERDAL CONSTA for schizophrenia and developed and manufacture VIVITROL for alcohol dependence. Alkermes ia a long-acting formulation of risperidone, a product of Janssen Pharmaceutica, Inc., a division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica International, a division of Cilag International (together, Janssen). The Company has developed VIVITROL, an extended-release Medisorb formulation of naltrexone, for the treatment of alcohol dependence in patients who are able to abstain from drinking in an outpatient setting and are not actively drinking prior to treatment initiation. Its pipeline includes extended-release injectable, pulmonary and oral products for the treatment of prevalent, chronic diseases, such as central nervous system disorders, addiction and diabetes. (Source: 10-K)
Acorda Therapeutics, Inc. (Acorda) is a commercial-stage, biopharmaceutical company engaged in the identification, development and commercialization of therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury (SCI) and other disorders of the central nervous system (CNS). The Company's marketed drug, Zanaflex Capsules, is approved by United States Food and Drug Administration (FDA) for the management of spasticity. Its lead product candidate, Fampridine-SR, is in Phase III development for the improvement of walking ability in patients with MS. The Company's preclinical programs also target other aspects of MS and SCI, as well as other CNS disorders, including stroke and traumatic brain injury. In February 2008, the Company acquired aminopyridine and pre-clinical assets of Neurorecovery, Inc.
Genta Incorporated (Genta) is a biopharmaceutical company engaged in pharmaceutical (drug) research and development. The Company focuses on the identification, development and commercialization of drugs for the treatment of cancer and related diseases. Genta’s research portfolio consists of two major programs: DNA/RNA Medicines and Small Molecules. The DNA/RNA Medicines program includes drugs that are based on using modifications of either deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) as drugs that can be used to treat disease. This program includes technologies, such as antisense, decoys and small interfering or micro RNAs. Genta’s lead drug from this program is an investigational antisense compound known as Genasense (oblimersen sodium injection). In September 2007, the Company announced that the Food and Drug Administration (FDA) has allowed the investigational new drug (IND) exemption that was submitted by the Company for its new drug known as G4544. (Source: 10-K)
Biomira is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Biomira's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients.
GPC Biotech AG is a biopharmaceutical company, which is engaged in the discovery, development and commercialization of anticancer drugs. Its lead product candidate is satraplatin, a platinum-based compound intended for use as a chemotherapy treatment. Unlike other platinum-based drugs, satraplatin is administered orally. In February 2008, the Company announced that it had decided to discontinue internal development of its 1D09C3 monoclonal antibody that was in Phase I clinical testing for relapsed/refractory B-cell lymphomas. The Company also has two kinase inhibitor compounds, RGB-344064 AND RGB-286638 in pre-clinical development. The ongoing Phase I trial evaluating satraplatin in combination with radiation therapy in non-small lung cancer is being conducted by the Company.
ImClone Systems Incorporated (ImClone) is a biopharmaceutical company that develops a portfolio of targeted biologic treatments designed to address the medical needs of patients with cancer. The Company focuses on two systems for treating cancer: growth factor blockers and angiogenesis inhibitors. Its commercially available product, ERBITUX (cetuximab), is an antibody approved by the United States Food and Drug Administration (FDA). On March 1, 2006, the FDA approved ERBITUX for use in combination with radiation therapy for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck (SCCHN) and as a single agent in recurrent or metastatic SCCHN. In addition to developing and commercializing ERBITUX, the Company has also advanced a number of investigational agents to various stages of clinical development, including those targeting angiogenesis and growth signaling mechanisms, which can be used to treat various kinds of cancer and other diseases.
Privacy Policy | Terms and Conditions | Do Not Sell My Personal Information | Websites Directory
Copyright © 2022 kwtbox.com. All Rights Reserved. US Business Directory